Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

被引：0

作者：

Park, W. ^{[1
]}

Lopes, G. ^{[1
]}

Kwon, D. ^{[2
]}

Florou, V. ^{[1
]}

Chae, Y. K. ^{[3
]}

Warsch, J. ^{[4
]}

Ishkanian, A. ^{[5
]}

Jahanzeb, M. ^{[6
]}

Mudad, R. ^{[1
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA

[5] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Tumor mutation burden; biomarker; Nivolumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.07-025

引用

页码：S2004 / S2005

页数：2

共 50 条

[21] Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Williams, L.
Shi, Q.
El Ferjani, B.
Hirschmann, M.
Ponce, D.
Dibaj, S.
Chandwani, S.
Roarty, E.
Rinsurongkawong, W.
Lewis, J.
Burke, T.
Cleeland, C.
Lee, J.
Roth, J.
Swisher, S.
Heymach, J.
Zhang, J.
Simon, G.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S327 - S327
[22] Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study)
Chouaid, C.
Levra, M. Giaj
Corre, R.
Calvet, C.
Gaudin, A-F.
Grumberg, V.
Jolivel, R.
Jouaneton, B.
Assie, J-B.
Cotte, F-E.
ANNALS OF ONCOLOGY, 2019, 30 : 521 - 521
[23] AN ECONOMIC EVALUATION OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) AFTER PRIOR CHEMOTHERAPY IN CHINA
Hu, S.
Fan, L.
Tang, Z.
Harrison, J. P.
Hertel, N.
Penrod, J. R.
May, J.
Young, K. C.
Holdgate, O.
VALUE IN HEALTH, 2019, 22 : S72 - S72
[24] Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy
Nie, Wei
Xu, Mi-Die
Gan, Lu
Zhang, Yi
Qian, Jie
Gu, Kai
Zhang, Xue-Yan
Wang, Hui-Min
Yan, Bo
Gu, Ping
Zhang, Bo
Wang, Shu-Yuan
Hu, Fang
Li, Chang-Hui
Zhong, Hua
Han, Bao-Hui
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (06) : 189 - 195
[25] Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer
Lin, Chen
Shi, Xun
Zhao, Jun
He, Qiong
Fan, Yun
Xu, Weizhen
Shao, Yang
Yu, Xinmin
Jin, Ying
FRONTIERS IN ONCOLOGY, 2020, 10
[26] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Yoshida, H.
Kim, Y. H.
Ozasa, H.
Nagai, H.
Sakamori, Y.
Tsuji, T.
Nomizo, T.
Funazo, T.
Yasuda, Y.
Hirai, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
[27] Clinical Potential of Tissue Tumor Mutational Burden (tTMB) and Blood TMB (bTMB) as a Biomarker in Non-Small Cell Lung Cancer
Zhou, J.
Zhou, J.
Chen, X.
Zhu, Y.
Fang, L.
Bao, Z.
Liu, R.
Cao, H.
Sun, W.
Zhang, T.
Lin, J.
Yu, B.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S370 - S370
[28] Tumor mutation burden as emerging biomarker in non-small cell lung cancer and beyond
Fischer, Rieke N.
Wolf, Juergen
TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S770 - S773
[29] Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
Cai, Liangliang
Bai, Hua
Duan, Jianchun
Wang, Zhijie
Gao, Shugeng
Wang, Di
Wang, Shuhang
Jiang, Jun
Han, Jiefei
Tian, Yanhua
Zhang, Xue
Ye, Hao
Li, Minghui
Huang, Bingding
He, Jie
Wang, Jie
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[30] The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, Laurent
Tomasini, Pascale
Barlesi, Fabrice
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 639 - 646

← 1 2 3 4 5 →